Table 3.

Follow-up Time, Number of Events, Incidence Rates, and Hazards Ratios; Incident Patients in Hemodialysis Centers Using Darbepoetin Alfa vs. Epoetin Alfa

Outcomes	Sample Size	F/U Time (person-y)	No. of Events	Incidence Rate (per 1000 person- y)	Unadjusted	Model 1	Model 2
Mortality	19932	21917.67	5550	253.22	1.12 (1.06, 1.20)	1.06 (1.00, 1.13)	1.05 (0.99, 1.12)
Cardiovascular Mortality	19932	21917.67	2037	92.94	1.11 (1.00, 1.24)	1.05 (0.94, 1.16)	1.05 (0.94, 1.16)
Stroke	9455	10456.87	248	23.72	0.98 (0.72, 1.34)	1.04 (0.76, 1.43)	1.02 (0.75, 1.41)
Myocardial infarction	9455	10363.29	372	35.90	1.17 (0.91, 1.50)	1.17 (0.91, 1.50)	1.16 (0.90, 1.50)
Composite^	9455	10190.52	1424	139.74	1.10 (0.97, 1.25)	1.09 (0.96, 1.24)	1.10 (0.96, 1.25)

Note: Unless otherwise indicated, values are given as hazard ratio (95% confidence interval). Time-to-event analyses started on the day of reported incidence of end-stage renal disease for mortality outcomes and on day 91 after end-stage renal disease for non-fatal and composite outcomes. Model 1 adjusted for age, sex, race, Hispanic ethnicity, Medicaid eligibility, and incidence year. Model 2 additionally adjusted for all comorbidities, body mass index, serum albumin concentration, and estimated glomerular filtration rate.

Multiple imputation was used to address missing data. Results from complete case analyses were not materially different (see Table S2).

^{^}Composite of stroke, myocardial infarction, and cardiovascular mortality